SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

The Boeing Co. is an aerospace company, which engages in the manufacture of commercial jetliners and defense, space, and security systems. It operates through the following segments: Commercial Airplanes (BCA), Defense, Space and Security (BDS), and Global Services (BGS). The Commercial Airplanes segment includes the development, production, and market of commercial jet aircraft and provides fleet support services, principally to the commercial airline industry worldwide. The Defense, Space and Security segment refers to the research, development, production and modification of manned and unmanned military aircraft and weapons systems for global strike, including fighter and combat rotorcraft aircraft and missile systems, global mobility, including tanker, rotorcraft and tilt-rotor aircraft, and airborne surveillance and reconnaissance, including command and control, battle management and airborne anti-submarine aircraft. The Global Services segment provides services to commercial and defense customers. The company was founded by William Edward Boeing on July 15, 1916, and is headquartered in Arlington, VA.

Boeing Co.

Boeing Co

Boeing is trending as geopolitical tensions elevate defense sector interest, alongside recent news of increasing aircraft deliveries and substantial new orders. The community is debating a potential defense-driven surge against the company's persistent production challenges and struggles to translate positive commercial developments into consistent stock performance.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is trending as disappointing delivery figures, including a recent January decline, and multiple analyst downgrades fuel community debate, with some viewing it as an oversold opportunity while others cite intense competition and a weakening sales outlook in the crowded EV market.

Fefe is a memecoin inspired by Matt Furie's book "Mindviscosity," published in 2020.  Follow FEFE, the alter ego of PEPE in the book “Mindviscosity” by Matt Furie.  Fefe is a main character in the book, who is a laid back and carefree frog living in a whimsical world. Fefe's relaxed and adventurous spirit captures the heart of this imaginative universe.  Launched stealth with no presale, zero taxes, LP burnt and contract renounced - TAX: 0/0 This narrative has its roots in a fascinating story.  Join us and become part of the $FEFE community today!

Fefe

FEFE is trending due to its strong, cult-like community relentlessly building around its narrative as the "third frog" and official representation of Pepe by creator Matt Furie. Despite market conditions, the community views it as a resilient and undervalued asset on Ethereum, widely discussed as the next major frog memecoin.

Eos Energy Enterprises, Inc. designs, manufactures, and deploys battery storage solutions for the electricity industry. It offers the Eos Znyth DC battery system product which designs to meet the requirements of the grid-scale energy storage market. The company was founded in 2008 and is headquartered in Edison, NJ.

Eos Energy Enterprises Inc - Ordinary Shares - Class A

Eos Energy (EOSE) is experiencing high volatility after its latest earnings report missed revenue and earnings expectations alongside weak guidance, triggering a sharp decline in share price. While some investors express significant concern over management's execution and credibility, others view the steep sell-off as an overreaction, pointing to strong revenue growth, a substantial backlog, and the long-term demand for its energy storage technology.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is trending amid heightened volatility in the meme coin sector, sparking a sharp division between confident long-term holders anticipating a rebound and a skeptical community segment dismissing it as a scam with an unsustainable supply.

Gorilla Technology Group, Inc. engages in the provision of video intelligence, Internet of Things (IoT) security, edge AI data analytics, and operational technology security solutions and services in Asia Pacific. It operates through the following segments: Video IoT, Security Convergence, and Other. The company was founded by Spincer Koh in May 2001 and is headquartered in London, the United Kingdom.

Gorilla Technology Group Inc

Gorilla Technology Group is trending as investors eagerly await its upcoming Q4 and full-year 2025 earnings announcement, with many hoping strong results will validate its revenue projections and trigger a significant price movement, while others debate the recent strategic acquisition for non-dilutive financing of AI infrastructure projects.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending as community members aggressively buy dips and accumulate, fueled by recent news of Bonk, Inc. welcoming a strategic partner and acquiring a substantial amount of tokens. Despite some skeptics calling it a 'pump and dump,' many traders are betting on a significant rebound, viewing it as 'casino time' within the broader meme coin sector.

Featured in Matt Furies latest book Cortex Vortex as Ratos nemesis. The character is also part of ZOGZ which confirms its real name.  Matt Furie, the artist best known for creating Pepe the Frog, has been working on a new book. The news comes from his editor, who goes by the handle @beuys_on_sale_ on Instagram. In a recent post, the editor hinted at an upcoming project featuring new characters named Gasspas and Rato. Gasspas’s visual appearance can be inferred from the artwork. In one illustration, Gasspas is depicted looming over two rats (Rato and Wat), gazing down at them in a menacing way (an image that has circulated among collectors). This inferred that Gasspas is Ratos nemesis in the new book Cortex Vortex reinforced by community quips that “cats eat rats”. Gasspas debuted as part of ZOGZ, a collection of 111 original NFT character illustrations by Matt Furie launched in May 2023.

Gasspas

Gasspas (GASS) is seeing heightened conversation around its recent price appreciation, with some in the community celebrating its "bullish" momentum and anticipating further gains, even as others express skepticism about its long-term viability, citing team abandonment and reported trading difficulties on platforms like Uniswap.

Cleveland-Cliffs, Inc. is a flat-rolled steel company, which engages in provision of iron ore pellets to the North American steel industry. It focuses on the production of metallic and coke, iron making, steelmaking, rolling and finishing, and downstream tubular components, stamping, and tooling. The company was founded in 1847 and is headquartered in Cleveland, OH.

Cleveland-Cliffs Inc

Cleveland-Cliffs is trending due to a contentious mix of post-earnings sentiment, widespread community discussion about the CEO's recent large share sale, and ongoing speculation regarding both steel tariffs and a potential strategic partnership with POSCO.

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digital is trending following strong earnings and optimistic guidance, bolstered by an expanded share repurchase program and a recent S&P credit rating upgrade. The community is actively discussing WDC's pivotal role in the ongoing "memory supercycle," driven by insatiable AI and cloud data storage demand that continues to outpace supply.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

<ul class="summary-bullets"><li>The outcome was unsurprising as Novo Nordisk Foundation controls 77% of the votes at the Novo Nordisk Annual General Meeting.</li><li>Sorensen said he intends to stay on in the role for a maximum of three years.</li></ul>Novo Nordisk (NVO) said on Friday that Lars Rebien Sørensen, the chair of its dominant shareholder, Novo Nordisk Foundation, has been elected as chair of the Board at the drugmaker, replacing Helge Lund.The outcome was unsurprising as Novo Nordisk Foundation controls 77% of votes at the Novo Nordisk Annual General Meeting through its investment company, Novo Holdings A/S. Sørensen was also previously the CEO of Novo from 2000 to 2016. &nbsp;<h2 class="st-heading-2">The New Chairman</h2>Sørensen, however, <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916459">said</a> that he intends to hold the position only for a period of two to three years. “My mandate is very clear. I have two important tasks together with the Board: First, to support the CEO and the management in its transformation plans to regain its competitive leadership, and second, prepare the way for my successor,” he said.Novo named Mike Doustdar as CEO of the company in August after Lars Fruergaard Jørgensen stepped down in May. Jørgensen decided to step down as per a mutual agreement with the Novo Nordisk board. The board stated that the change is being made in light of Novo Nordisk's recent market challenges, the company’s declining share price since mid-2024, and discussions with the Novo Nordisk Foundation.Sorensen on Friday also said that he is looking to “strengthen the board with some qualifications,” with recent pharma or over-the-counter business experience. “We might see a future where our GLP-1 product is going in this direction,” he said, highlighting the company’s ambitions to make its drugs over-the-counter without prescription.Minority shareholders, including Norway’s sovereign wealth fund and CalSTRS, opposed Sorensen’s appointment. Proxy advisor ISS also urged investors to abstain, citing “limited transparency and accountability to minority shareholders.”<h2 class="st-heading-2">Other appointments</h2>Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday.The new appointment comes amid Novo’s intense competition in the weight-loss drug market with its U.S. counterpart, Eli Lilly, and a dramatic board rupture last month, in which disagreements over governance principles between Novo’s board and the foundation prompted more than half of the supervisory board to resign.<a href="https://stocktwits.com/symbol/NVO">Shares of NVO</a> traded 2% lower by Thursday noon. On Stocktwits, retail sentiment around NVO rose from ‘bearish’ to ‘neutral’ territory over the past 24 hours while message volume jumped from ‘normal’ to ‘high’ levels.A Stocktwits user expressed optimism about the stock, citing the price-to-earnings valuation.<stembedurl>https://stocktwits.com/Bassfisher89/message/636229521</stembedurl>Another expressed hopes for the stock’s prospects.<stembedurl>https://stocktwits.com/Natetruu/message/636213210</stembedurl>NVO shares are down by 44% this year and by 54% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/scholar-rock-eyes-reapplication-for-approval-of-muscle-atrophy-therapy-in-2026/cLPQ17HRE4q">Why Did Scholar Rock Soar 26% Today?</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

In this photo illustration, the logo of Novo Nordisk is displayed on a smartphone screen on September 10, 2025 in Chongqing, China. 

Novo Nordisk Brings Back Former CEO To Lead Board

Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday. 

Equity

Meanwhile, Cees de Jong was elected vice chair, replacing Henrik Poulsen, while Britt Meelby Jensen and Stephan Engels were appointed as members of the board at the meeting on Friday. 


The U.S. Food and Drug Administration has sent a letter to Novo Nordisk (NVO) CEO Maziar Mike Doustdar regarding the company’s promotional communication featuring Oprah Winfrey, alleging that the video is false or misleading.The video originally appeared on ABC as a Primetime Oprah Special on March 18, 2024. It also subsequently appeared on Hulu. The video is a 42-minute special program hosted by Oprah Winfrey, featuring patient testimonials from individuals who struggle with obesity and excessive weight, including those who have used Novo’s Wegovy, Ozempic, or Victoza.The FDA <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/warning-letters/novo-nordisk-inc-716495-09092025">alleged</a> in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. The video was also not submitted at the time of initial dissemination or publication as required by law, the agency said.“These violations are concerning from a public health perspective because the promotional communication creates a misleading impression regarding the safety of Wegovy, Ozempic, and Victoza, which are drugs with multiple serious, potentially life-threatening risks,” the agency said.The FDA also noted that obesity and type 2 diabetes are significant public health concerns in the U.S., and consumers who seek medical treatment for these conditions should receive truthful and nonmisleading information regarding the serious risks associated with the use of the drugs. While Novo’s Wegovy is used for weight management, its Ozempic and Victoza are used to treat type 2 diabetes.The FDA said that several advisory comments dated as long back as 2010 addressed draft promotional communications for Victoza with certain similarities to the aforementioned video. The agency expressed concerns that <a href="https://stocktwits.com/symbol/NVO">Novo</a> is promoting the three drugs in a manner that fails to present the serious risks of these drug products in a truthful and nonmisleading manner, despite the FDA’s prior comments.While the video includes numerous representations of the benefits of Wegovy, Ozempic, and Victoza made by representatives of Novo Nordisk, it omits important risk information or minimizes the risks associated with these drug products, the FDA said. Only four minutes in total were devoted to the important risks associated with GLP-1 drugs, such as Wegovy, the FDA said.The video also omits reference to how the drugs are contraindicated in patients with a personal or family history of Medullary Thyroid Cancer or in patients with Multiple Endocrine Neoplasia syndrome type 2, it added. The omissions are exacerbated by statements from Amanda Velazquez, a paid consultant of Novo, made on the video, the FDA said.NVO stock is down by 33% this year and by 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/hims-and-hers-stock-tumbles-7-percent-after-fda-letter/chwyNFWRdzV">Hims &amp; Hers Stock Draws Investor Attention After Tumbling 7% – Here’s What Happened</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Ozempic manufactured by Novo Nordisk packaging is seen in this illustration photo taken in a pharmacy in Krakow, Poland on December 7, 2023. (Photo by Jakub Porzycki/NurPhoto via Getty Images)

US FDA Alleges Novo Nordisk’s Video On Weight-loss Drugs Featuring Oprah Winfrey Is ‘False Or Misleading’ 

The FDA alleged in a letter dated September 9 that the video misbranded Novo’s Wegovy, Ozempic, and Victoza, making its distribution violative. 

Novo Nordisk (NVO) announced on Tuesday that its new obesity treatment, Cagrilintide, reduced body weight by 11.8% after 68 weeks in a late-stage study.The company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/content/nncorp/global/en/news-and-media/news-and-ir-materials/news-details.html?id=916427">reported</a> an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in the trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy, plus lifestyle intervention, for adults with obesity or overweight and a weight-related comorbidity without diabetes. The above levels of weight reduction were observed in participants who adhered to the treatment. Regardless of adherence, average weight loss with Cagrilintide was 11.5% compared to 3.0% with placebo after 68 weeks.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> stayed within the ‘bearish’ territory over the past 24 hours, while message volume rose from ‘low’ to ‘normal’ levels. Shares of the company traded over 2% higher at the time of writing.<figure class="image"><img style="aspect-ratio:575/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_09_16_at_9_59_21_AM_png_2efadb4b5b.webp" alt="NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits" width="575" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 9:59 a.m. ET on Sept. 16, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expressed disappointment that the stock rallied only 2-3% on good news.<stembedurl>https://stocktwits.com/King990/message/628811943</stembedurl>Cagrilintide works differently from currently approved GLP-1-based treatments for weight loss, including Novo’s Wegovy and Eli Lilly’s Zepbound. The new drug mimics the naturally occurring hormone amylin that helps control blood glucose levels and appetite by slowing gastric emptying, reducing glucagon secretion, and promoting satiety.The company also stated that approximately one in three participants receiving Cagrilintide achieved 15% or more weight loss, compared to approximately one in 20 participants receiving a placebo, when patients adhered to the treatment.Novo stated that the drug was well-tolerated, while adding that the most common side effects were gastrointestinal, including nausea, vomiting, diarrhoea, and constipation. These side effects were mainly temporary and mild to moderate, and 1% of participants discontinued the study due to nausea, compared to 0.1% of participants who received a placebo.“We’re excited that these data, the first phase 3 data of a next-generation amylin therapy, show promise, and we look forward to further investigating cagrilintide’s potential in the dedicated phase 3 RENEW programme,” said Martin Holst Lange, chief scientific officer and executive vice president of Research and Development at Novo Nordisk.Another late-stage programme investigating the efficacy and safety of Cagrilintide in people with obesity or overweight is due to start in the fourth quarter of this year.Separately, Bloomberg <a target="_blank" rel="noopener noreferrer nofollow" href="https://bloomberg.com/news/articles/2025-09-16/novo-plans-to-seek-us-approval-for-its-high-dose-obesity-shot?sref&amp;#61;8QBk7toa">reported</a> on Tuesday that Novo plans to seek U.S. regulatory approval for a high-dose version of Wegovy. Though the drugmaker hasn’t yet formally announced its U.S. plans, it intends to file for the U.S. Food and Drug Administration approval, said Lange at the European Association for the Study of Diabetes conference in Vienna, according to the report.NVO stock is down 34% this year and by about 58% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/us-regulator-opens-probe-into-174000-plus-tesla-model-y-vehicles/chwyiNgRdz5">US Regulator Opens Probe Into 174,000-Plus Tesla Model Y Vehicles – Check Out Why</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, a Novo Nordisk logo is displayed on a smartphone with stock market percentages in the background. (Photo Illustration by Omar Marques/SOPA Images/LightRocket via Getty Images)

Novo Nordisk Says New Obesity Treatment Achieved 11.8% Body Weight Reduction In Late-Stage Study

The company reported an average weight loss of 12.5 kg, compared to 2.5 kg with the placebo, in a trial evaluating the efficacy and safety of once-weekly Cagrilintide 2.4 mg monotherapy. 

Danish drugmaker Novo Nordisk (NVO) has entered into a multi-year research collaboration with Replicate BioScience to develop new therapeutic candidates, the privately held clinical stage company stated on Thursday.The collaboration will bring together Novo’s therapeutic knowledge and drug development expertise with Replicate’s novel srRNA platform to develop new therapeutic candidates to treat obesity, type 2 diabetes, and other cardiometabolic diseases, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://replicatebioscience.com/replicate-bioscience-announces-partnership-with-novo-nordisk-to-unlock-self-replicating-rna-therapies-for-obesity-and-diabetes/">said</a>.On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO stock</a> trended within the ‘bearish’ territory over the past 24 hours, while message volume remained at ‘low’ levels. According to Stocktwits data, retail chatter about the stock increased by about 157% over the past 30 days. Shares of the company traded 1% lower at the time of writing.<figure class="image"><img style="aspect-ratio:577/60;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_28_at_10_55_20_AM_png_5dd1ac88ba.webp" alt="NVO's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 28, 2025 | Source: Stocktwits" width="577" height="60"><figcaption>NVO's Sentiment Meter and Message Volume as of 10:55 a.m. ET on Aug. 28, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user said that they have purchased more shares of the company.<stembedurl>https://stocktwits.com/bginvest/message/626846711</stembedurl>Under the new deal, Novo Nordisk will receive a defined, exclusive, and worldwide license to use Replicate’s self-replicating RNA platform for the development and commercialization of treatments. Meanwhile, Replicate will receive research funding and is eligible to receive up to $550 million from Novo, including an up-front cash payment and potential milestone payments. Replicate is also eligible to receive tiered royalties on future product sales as part of the deal.Last month, Novo, which is battling competition from its U.S. rival Eli Lilly, lowered its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and diabetes drug Ozempic for the second half of the year.The firm now expects sales growth of 8% to 14% during the year at a constant exchange rate, down from its previous estimate of 13% to 21%. Operating profit growth is now expected to be 10% to 16%, down from its prior outlook of 16% to 24%.Last week, it was reported that the drugmaker has implemented a hiring freeze, which will apply across all markets and departments, with an exemption for business-critical roles. Former CEO of Novo Nordisk, Lars Fruergaard Jørgensen, had earlier stated that the company is taking measures to sharpen its commercial execution and ensure efficiencies in cost base while continuing to invest in future growth.NVO stock is down 35% this year and approximately 59% over the past 12 months.&nbsp;Also See: <a href="https://stocktwits.com/news-articles/markets/equity/teva-pharma-announces-fda-approval-for-generic-weight-loss-medication/chs6ffWRdmt">This Pharma Stock Is Down 19% In 2025 But Just Received An ‘Explosive News’ – Find Out More</a>For updates and corrections, email newsroom[at]stocktwits[dot]com

This Pharma Major’s Stock Has Lost 59% Of Its Value In A Year – Why Is It Drawing Investor Interest Today?

Novo Nordisk has entered into a collaboration with Replicate BioScience under which it will receive a defined, exclusive, worldwide license to use the latter’s self-replicating RNA platform to develop and commercialize treatments.

Danish drugmaker Novo Nordisk (NVO) has implemented a hiring freeze, which will apply across all markets and departments, Bloomberg reported on Wednesday, citing a company spokesperson.Business-critical roles, however, would be exempted from the hiring freeze, the report <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.bloomberg.com/news/articles/2025-08-20/novo-nordisk-s-new-ceo-starts-hiring-freeze-in-cost-cutting-push-mejscm29">said</a>. On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">Novo</a> remained within the ‘neutral’ territory over the past 24 hours, while message volume fell from ‘high’ to ‘normal’ levels.<figure class="image"><img style="aspect-ratio:564/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_20_at_7_07_43_AM_png_be5874fe43.webp" alt="NVO's Sentiment Meter and Message Volume as of 7:08 a.m. ET on Aug. 20, 2025 | Source: Stocktwits" width="564" height="62"><figcaption>NVO's Sentiment Meter and Message Volume as of 7:08 a.m. ET on Aug. 20, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user expects the stock to trade over $100 in a year.<stembedurl>https://stocktwits.com/Eesnimi/message/625897097</stembedurl>Another user opined that the stock can rally up to $70 if it can break the $55 mark.<stembedurl>https://stocktwits.com/trading_momentum/message/625893966</stembedurl>Former CEO, Lars Fruergaard Jørgensen, said earlier this month that the company is taking measures to sharpen its commercial execution further, and ensure efficiencies in cost base while continuing to invest in future growth. Novo’s new CEO, Maziar Mike Doustdar, took charge on August 7.Last month, the company, battling competition from its U.S. rival Eli Lilly, <a href="https://stocktwits.com/news-articles/markets/equity/novo-nordisk-slashes-full-year-guidance/cho9UwAR5yE">lowered</a> its full-year 2025 outlook, citing lower growth expectations for its blockbuster weight loss drug Wegovy and diabetes drug Ozempic for the second half of the year.The firm now expects sales growth of 8% to 14% during the year at a constant exchange rate, down from its previous estimate of 13% to 21%. Operating profit growth is now expected to be 10% to 16%, down from its prior outlook of 16% to 24%.The company now sees lower growth for Wegovy in the U.S. obesity market and for Ozempic in the U.S. diabetes market, as well as lower-than-expected penetration for Wegovy in select international operations markets.Novo’s <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.com/careers/find-a-job/career-search-results.html?searchText=&amp;countries=&amp;categories=">website</a> currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in Denmark. According to the company, it employs over 77,000 people in 80 offices around the world.NVO stock is down by 36% this year and by about 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ioc-bpcl-reportedly-resume-russian-crude-purchase-as-discounts-widen/chsiZrQRdh3">IOC, BPCL Reportedly Resume Russian Crude Purchase As Discounts Widen</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Novo Nordisk Freezes Hiring To Cut Costs, Says Report: Retail Sees Stock Surpassing $100-Mark In A Year

Novo’s website currently shows multiple job openings in the U.S. and mainland China, but merely eight open positions in Denmark.

Danish drugmaker Novo Nordisk (NVO) on Tuesday said that its blockbuster drug Ozempic is now approved in Canada to reduce the risk of kidney function decline, end-stage kidney disease, and cardiovascular death in patients with type 2 diabetes and chronic kidney disease (CKD).On Stocktwits, retail sentiment around <a href="https://stocktwits.com/symbol/NVO">NVO</a> trended within the ‘neutral’ territory over the past 24 hours, while message volume remained at ‘normal’ levels. According to data from Stocktwits, retail chatter around the stock jumped 67% over the past 24 hours and by about 197% over the past seven days as of early hours on Tuesday. &nbsp;<figure class="image"><img style="aspect-ratio:626/62;" src="https://news.stocktwits-cdn.com/Screenshot_2025_08_19_at_1_02_48_PM_png_e2a2c52a54.webp" alt="NVO's Sentiment Meter and Message Volume as of 1:03 p.m. ET on Aug. 19, 2025 | Source: Stocktwits" width="626" height="62"><figcaption>NVO's Sentiment Meter and Message Volume as of 1:03 p.m. ET on Aug. 19, 2025 | Source: Stocktwits</figcaption></figure> A Stocktwits user said that they do not see much downside for the stock.<stembedurl>https://stocktwits.com/bullish51892/message/625797538</stembedurl>The approval from Health Canada for the indications is based on the results of a trial in which Semaglutide 1 mg demonstrated a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo. Semaglutide is the active ingredient in Ozempic.The trial was initiated in 2019 and was stopped early due to efficacy, based on a recommendation from an Independent Data Monitoring Committee, the company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.novonordisk.ca/content/dam/nncorp/ca/en/press-releases/ozempic-ckd-indication-press-release-english-aug192025.pdf">said</a>.Ozempic is already indicated for the once-weekly treatment of adult patients with type 2 diabetes mellitus to improve glycemic control. It was approved by Health Canada in 2018.CKD and type 2 diabetes are interconnected. Around 40% people with type 2 diabetes develop the disease. CKD is defined as the presence of kidney damage, or a decreased level of kidney function, for a period of three months or more. It is estimated to impact nearly four million Canadians.Novo is currently attempting to increase the use cases for its GLP-1 category drugs, including Ozempic and the weight-loss drug Wegovy. Last week, the company said that the U.S. Food and Drug Administration has also approved Wegovy for the treatment of noncirrhotic metabolic dysfunction-associated steatohepatitis (MASH) in adults with moderate to advanced liver fibrosis. MASH is a serious liver disease characterized by fat accumulation, inflammation, and liver cell damage.NVO stock is down by 37% this year and by about 60% over the past 12 months.&nbsp;Read also: <a href="https://stocktwits.com/news-articles/markets/equity/ptc-therapeutics-stock-in-limelight-after-fda-refuses-approval-for-drug-to-treat-neurodegenerative-disease/chsgFLxRdW5">PTC Therapeutics Stock In The Spotlight After FDA Refuses Approval For Drug To Treat Neurodegenerative Disease, Analysts Are Divided</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Health Canada Approves Novo’s Ozempic to Reduce Risk Of Kidney Function Decline, Cardiovascular Death

The approval from Health Canada for the indications is based on the results of a trial in which Semaglutide 1 mg demonstrated a 24% reduction in the risk of kidney disease progression and cardiovascular and kidney mortality compared to placebo. 

Health Canada Approves Novo’s Ozempic To Reduce Risk Of Kidney Function Decline, Cardiovascular Death

NuShares ETF Trust - Nuveen Dividend Growth ETF

Day trading

Swing trading

Long-term investing

Sitting in cash

Markets have been volatile, with macro headlines and earnings driving sharp moves. How are you positioning right now?

Drop your approach below 👇

NDVG
NuShares ETF Trust - Nuveen Dividend Growth ETF

Feed

News

Sentiment

Fundamentals

Info

Poll

Latest NDVG News

NDVGNuShares ETF Trust - Nuveen Dividend Growth ETF